drugset / Trial / NCT02173665
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses of BI 1356 BS Administered to Healthy Male Subjects
RandomizedSingle-groupDouble-blindTreatment
Summary
The objective of the current study was to investigate safety, tolerability, pharmacokinetics and pharmacodynamics of BI 1356 BS.
Timeline
- Start
- 2004-10
- Primary completion
- 2004-12
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Linagliptin | Unknown | 2.5 mg | Oral |
| Subject | Linagliptin | Unknown | 5 mg | Oral |
| Subject | Linagliptin | Unknown | 25 mg | Oral |
| Subject | Linagliptin | Unknown | 600 mg | Oral |
Indications
No indication recorded.